HCMHUTCHMED (China) Ltdvs its industry peers
A metric-by-metric comparison of HUTCHMED (China) Ltd against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCMThis | $11.4B#2 | 25.2x#1 | 9.2x#1 | 20.8x#1 | -13.0%#1 | 1111.0%#1 | -7.1%#1 | 36.9%#1 | 0.0%#1 | — | -15.1%#3 | — |
| GSK | $210.3B#1 | — | — | — | — | — | — | — | — | — | 5.2%#2 | — |
| HELP | $194M#4 | — | — | — | — | — | — | — | — | — | 33.5%#1 | — |
| HMDCF | — | — | — | — | -13.0%#1 | 1111.0%#1 | -7.1%#1 | 36.9%#1 | 0.0%#1 | — | — | — |
| HSTC | — | — | — | — | — | -0.8%#4 | — | -11.8%#3 | — | — | — | — |
| HYFT | $50M#6 | — | — | — | — | — | — | — | — | — | — | — |
| IFRX | $117M#5 | — | — | — | — | — | — | — | — | — | — | — |
| IMMP | $4.4B#3 | — | — | — | — | — | — | — | — | — | -91.8%#5 | — |
| IMRX | — | — | — | — | -100.0%#3 | 8.2%#3 | — | -33.2%#4 | — | — | -43.8%#4 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice